Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Ref.	Study design	Age, years (T: C)	Sex (M/F, T: C)	Sample size (T: C)	Treatment group	Control group	Child-Pugh classification
Lee et al[15], 2024	Retrospective cohort study	63: 59	120/17: 45/7	137: 52	Regorafenib	Nivolumab	Regorafenib group: Child-Pugh B (24.1%); nivolumab group: Child-Pugh B (42.3%)
Adhoute et al[16], 2022	Retrospective, multicenter	68: 68	53/5: 24/4	58: 28	Regorafenib	Cabozantinib	Combined A/B proportion approximately 24%-25%
Casadei-Gardini et al[19], 2021	Retrospective study	Not reported	222/46: 264/67	278: 331	Regorafenib	Cabozantinib	Not reported
Iavarone et al[18], 2021	Retrospective study	60: 61	27/9: 38/7	36: 45	Regorafenib	BSC	Not reported
Kuo et al[17], 2021	Retrospective study	63.4 ± 10.7: 62.2 ± 10.1	44/14: 23/9	58: 32	Regorafenib	Nivolumab	Not reported
Choi et al[21], 2020	Retrospective study	58.5 ± 9.4: 56.9 ± 10.0	202/21: 125/25	223: 150	Regorafenib	Nivolumab	Child-Pugh A: 132 patients; Child-Pugh B: 71 patients
Lee et al[20], 2020	Retrospective cohort study	62: 61	83/54: 39/9	102: 48	Regorafenib	Nivolumab	Not reported
Finn et al[22], 2018	RCT	64: 62	333/46: 171/23	379: 194	Regorafenib	Placebo	Child-Pugh A only
Bruix et al[23], 2017	RCT	64: 62	333/46: 171/23	379: 194	Regorafenib	Placebo	Child-Pugh A only

RCT: Randomized controlled trial; T: Treatment group; C: Control group; M: Male; F: Female; BSC: Best supportive care.